Amyris (NASDAQ:AMRS) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 13th. Analysts expect Amyris to post earnings of ($0.17) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
NASDAQ AMRS opened at $6.34 on Friday. The stock has a market capitalization of $474.60 million, a P/E ratio of -2.08 and a beta of 0.27. Amyris has a 12 month low of $2.93 and a 12 month high of $9.28.
In other Amyris news, insider John Melo sold 5,195 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $7.50, for a total value of $38,962.50. Following the completion of the transaction, the insider now directly owns 743,713 shares of the company’s stock, valued at $5,577,847.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eduardo Alvarez bought 11,877 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was acquired at an average cost of $8.45 per share, with a total value of $100,360.65. Following the completion of the purchase, the chief operating officer now owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 40,877 shares of company stock valued at $316,061 and sold 8,807,465 shares valued at $54,789,082. 21.80% of the stock is currently owned by insiders.
A number of equities research analysts recently commented on the company. ValuEngine upgraded Amyris from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. HC Wainwright set a $15.00 price objective on Amyris and gave the company a “buy” rating in a report on Friday, September 28th. BidaskClub downgraded Amyris from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Finally, B. Riley set a $10.00 target price on Amyris and gave the company a “buy” rating in a research note on Wednesday, October 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $9.13.
ILLEGAL ACTIVITY WARNING: This news story was reported by WKRB News and is the property of of WKRB News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/11/11/amyris-amrs-to-release-earnings-on-tuesday.html.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Read More: What is the Rule of 72?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.